🔎 Trials Near Me

Hjem › Myelofibrose › Alabama

Myelofibrose kliniske forsøg i Alabama

7 studier for Myelofibrose søger deltagere på steder i Alabama.

Byer i Alabama

Officiel studietekst (engelsk)

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

  • University of Alabama, Birmingham
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04176198

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  • University of Alabama At Birmingham, Birmingham
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. jul. 2026 · NCT07441694

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

  • University of Alabama at Birmingham, Birmingham
RekruttererFase 1
4 Weeks – 75 Years · Alle køn · Opdateret 13. apr. 2026 · NCT06047886

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

  • University of Alabama Birmingham, Birmingham
RekruttererFase 2
Alder 18 til 66 · Alle køn · Opdateret 17. mar. 2026 · NCT06859424

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Birmingham
  • Massive Bio SYNERGY-AI site, Mobile
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  • UAB Hospital, Birmingham
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2025 · NCT06479135

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

  • University of Alabama at Birmingham, Birmingham
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 21. feb. 2023 · NCT05280509

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.